Novel EHE PDX model used for drug sensitivity
- Topics:
- AACR2023
- bone
- Drug sensitivity
- EHE cancer
- liver
- lungs
- OBP
- PDX model
Categories
Filter by Topics
AACR2023 ALK aplastic anemia AA Autoimmune Disorder B-cell lymphoma Biology of neoplasia Biomarkers Bladder Cancer bone Brain Breast Cancer CD3 Cells Cerebrospinal Fluid clinical trial cold tumor Colorectal cancer Comparison study CXCL12 Cytokines Developmental Immunotherapy Developmental Therapeutics Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug sensitivity EHE cancer Encephalophy EPCORE NHL-1 ERBB3 FFPE Gene Expression Profiling Genetic Polymorphism Heart Histone Deacetylase Inhibitors hot tumor HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTP Immune Checkpoint Inhibitors Immune Response Immune-related Colitis Immuno-Oncology IMMUNOSARC Immunotherapy IOA- 244 IRP Kidney Liposarcoma liver Liver Lung lungs lymphoma Lymphoma melanoma Melanoma Microenvironment miRNA miRNA WTA Molecular Characterization Nash and Fibrosis Natural Killer Cells Nestin+ Neurologic non-Hodgkin Lymphoma Non-Hodgkin lymphoma NHL OBP Oesophageal Adenocarcinoma Oral cancer oral squamous cell carcinoma OSCC PanB Pancreas pancreatic ductal adenocarcinoma PDAC Parkinson's Disease Pathway Analysis PDX model PI3K inhibitors PIP Plasma Platform Comparison Programmed cell death protein 1 Prostate qNPA qPCR Radioimmunotherapy Rheumatoid Arthritis Sarcoma Serum Signatures soft tissue sarcoma Sub-typing Survival plots T cells Thymic Carcinoma Tislelizumab TME Transplantation Treatment Outcome Treatment Targets Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Zanubrutinlb2023
53P Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation
2022
SABCS 2022: HER2-06: Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping
SABCS 2022: PD4-02: Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy
SABCS 2022: PD17-06: Immunohistochemical Markers and Determinants of Clinical Response in the Penelope-B Trial
SABCS 2022: PD-17-05: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials.
Page last updated May 22, 2023